Table 1.
Summary of Patient Characteristics.
| Case | Age (years) | Sex | Dx | BH (cm) | BW (kg) | BMI (kg/m2) | HbA1c (%) | eGFR (mL/min/ 1.73 m2) | UP (g/gCr) | Prednisolone dose (mg) | Diet therapy (kcal/kg) | DPP-4 inhibitor | Number of days of diet therapy before first CGM test (days) | Number of days of DPP-4 inhibitor before second CGM test (days) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial | Before | After | Before | After | Name | Initial dose (mg) | ||||||||||||
| 1 | 60 | M | IgAN | 161.2 | 67.2 | 25.9 | 5.7 | 61.3 | 4.7 | 30*, ## | 25, # | 25, # | 31.5 | 31.5 | Alo | 25 | 14 | 6 |
| 2 | 47 | F | LDKT | 158.4 | 47.8 | 19.1 | 5.8 | 59.8 | 0.1 | 25*, ## | 15, ## | 5, # | 32.6 | 32.6 | Lina | 5 | 60 | 4 |
| 3 | 65 | M | MCNS | 164.3 | 61.5 | 22.8 | 6.1 | 53.8 | 5.9 | 50, ## | 50, ## | 50, ## | 30.3 | 33.7 | Lina | 5 | 32 | 5 |
| 4 | 60 | F | MPA | 152.7 | 45.6 | 19.6 | 6.3 | 77.4 | 0.1 | 50, ## | 45, ## | 40, ## | 27.3 | 27.3 | Teneli | 20 | 43 | 12 |
| 5 | 42 | F | NS | 152.0 | 38.7 | 16.8 | 6.4 | 107.0 | 7.2 | 50*, ## | 50, ## | 40, ## | 23.6 | 31.5 | Vilda | 100 | 15 | 12 |
| 6 | 65 | F | MN | 157.5 | 53.7 | 21.6 | 5.9 | 88.5 | 6.9 | 40, # | 40, # | 40, # | 29.3 | 29.3 | Sita | 50 | 39 | 14 |
| 7 | 74 | F | CSS | 157.1 | 52.9 | 21.4 | 5.2 | 55.5 | 0.0 | 55, ## | 50, ## | 40, ## | 27.6 | 27.6 | Alo | 25 | 56 | 25 |
| 8 | 74 | F | MPA | 149.0 | 41.2 | 18.6 | 6.2 | 7.0 | 2.5 | 25, # | 25, # | 25, # | 32.8 | 32.8 | Vilda | 100 | 18 | 4 |
| 9 | 57 | M | DM | 174.7 | 62.7 | 20.5 | 5.9 | 74.5 | 0.2 | 60, ## | 60, ## | 55, ## | 29.8 | 29.8 | Vilda | 100 | 13 | 8 |
| 10 | 82 | M | IP | 156.0 | 46.0 | 18.9 | 5.8 | 36.5 | 0.1 | 30*, ## | 20, # | 20, # | 29.9 | 29.9 | Sita | 25 | 7 | 10 |
| 11 | 58 | M | MCNS | 178.0 | 78.5 | 24.8 | 6.3 | 66.3 | 7.8 | 60, ## | 60, ## | 60, ## | 25.8 | 25.8 | Alo | 25 | 7 | 9 |
*These patients received methyl-prednisolone pulse therapy prior to maintenance glucocorticoid therapy, #Single daily dosing after breakfast, ##Twice daily dosing after breakfast and lunch, Alo: alogliptin, After: after DPP-4 inhibitor treatment, Before: before DPP-4 inhibitor treatment, BH: body height, BMI: body mass index, BW: body weight, CSS: Churg-Strauss syndrome, CGM: continuous glucose monitoring, DM: dermatomyositis, DPP: dipeptidyl peptidase, Dx: diagnosis, eGFR: estimated glomerular filtration rate, F: female, IgAN: immunoglobulin A nephropathy, IP: interstitial pneumonia, LDKT: living-donor kidney transplantation, Lina: linagliptin, M: male, MAGE: mean amplitude of glycemic excursion, MCNS: minimal change nephrotic syndrome, MN: membranous nephropathy, MPA: microscopic polyangiitis, MPGN: membranoproliferative glomerulonephritis, NS: nephrotic syndrome, Sita: sitagliptin, Teneli: teneligliptin, UP: urine protein, Vilda: vildagliptin